CP671305
- Product Name
- CP671305
- CAS No.
- 445295-04-5
- Chemical Name
- CP671305
- Synonyms
- CS-2886;CP671305;UNII-9LH034R9R9;CP671305, 10 mM in DMSO;CP-671305; CP 671305; CP671305; UNII-9LH034R9R9;445295-04-5;CP 671305,Inhibitor,Phosphodiesterase (PDE),CP671305,CP-671305,inhibit;(R)-2-(4-((2-(benzo[d][1,3]dioxol-5-yloxy)nicotinamido)methyl)-3-fluorophenoxy)propanoic acid;Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2R)-
- CBNumber
- CB53175535
- Molecular Formula
- C23H19FN2O7
- Formula Weight
- 454.4
- MOL File
- 445295-04-5.mol
CP671305 Property
- storage temp.
- Store at -20°C
- solubility
- DMF: 50 mg/ml; DMSO: 25 mg/ml; Ethanol: 3 mg/ml; PBS (pH 7.2): 2 mg/ml
- form
- A crystalline solid
- color
- White to off-white
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 26743
- Product name
- CP 671,305
- Packaging
- 1mg
- Price
- $44
- Updated
- 2024/03/01
- Product number
- 26743
- Product name
- CP 671,305
- Packaging
- 10mg
- Price
- $341
- Updated
- 2024/03/01
- Product number
- 26743
- Product name
- CP 671,305
- Packaging
- 5mg
- Price
- $193
- Updated
- 2024/03/01
- Product number
- CS-6774
- Product name
- CP671305
- Purity
- 99.95%
- Packaging
- 25mg
- Price
- $250
- Updated
- 2021/12/16
- Product number
- BC161230
- Product name
- CP 671305
- Packaging
- 2mg
- Price
- $250
- Updated
- 2021/12/16
CP671305 Chemical Properties,Usage,Production
Description
CP 671,305 is a potent inhibitor of phosphodiesterase 4D (PDE4D; IC50 = 3 nM). It is selective for PDE4D over PDE4A, -B, and -C (IC50s = 310, 287, and 3,858 nM, respectively), as well as over PDE1-3 and 5 (IC50s = >5,000 nM for all). CP 671,305 inhibits release of leukotriene E4 (LTE4; ) from eosinophils (IC50 = 52 nM) and LTB4 from neutrophils (IC50 = 106 nM). In vivo, CP 671,305 inhibits antigen-induced pulmonary eosinophil influx in cynomolgus monkeys in a dose-dependent manner.
Uses
CP671305 is a potent, orally active, selective inhibitor of phosphodiesterase-4-D, and possesses high activities.
in vivo
CP-671,305 pharmacokinetics are largely unaltered, and compromised biliary clearance of CP-671,305 is compensated by increased urinary clearance[1]. CP-671,305 demonstrates generally favourable pharmacokinetic properties, systemic plasma clearance after intravenous administration is low in Sprague-Dawley rats (9.60 ± 1.16 mL/min/kg), beagle dogs (2.90 ± 0.81 mL/min/kg) and cynomolgus monkeys (2.94 ± 0.87 mL/min/kg) resulting in plasma half-lives > 5 h. Moderate to high bioavailability in rats (43-80%), dogs (45%) and monkeys (26%) is observed after oral dosing. In rats, oral pharmacokinetics are dose dependent over the dose range studied (10 and 25 mg/kg)[2].
References
[1] Kalgutkar AS, et al. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab Dispos. 2007 Nov;35(11):2111-8. Epub 2007 Aug 8. DOI:10.1124/dmd.107.016162
[2] Kalgutkar AS, et al. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica. 2004 Aug;34(8):755-70. DOI:10.1080/00498250400005682
CP671305 Preparation Products And Raw materials
Raw materials
Preparation Products
CP671305 Suppliers
- Tel
- --
- Fax
- --
- sales@carbosynth.com
- Country
- United Kingdom
- ProdList
- 6005
- Advantage
- 58